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Our Bodies, Our
Cells: FDA
Regulation of
Autologous Adult
Stem Cell Therapies
By Mary Ann Chirba, J.D., D.Sc., M.P.H. and Alice A. Noble,
J.D., M.P.H.
Stem cells have been an endless
source of fascination and
controversy since Dolly the sheep
was cloned in 1996. This month’s
announcement of a cloned human
embryo from a single skin cell [1]
came on the heels of Sir John B.
Gurdon and Dr. Shinya
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Yamanaka’s receipt of the 2012
Nobel for Physiology and Medicine for their work with induced
pluripotent stem cells. Pluripotent stem cells can be embryonic
or induced. Embryonic stem cells (ESCs) can generally be
obtained from human embryos or by cloning embryos through
somatic cell nuclear transfer (SCNT), as was done for Dolly. 
Gurdon and Yamanaka demonstrated that pluripotent cells may
also be formed by reprogramming adult cells to an embryonic
state, resulting in induced pluripotent stem (iPS) cells without
having to use eggs or cloning, or destroy embryos. However
derived, pluripotent cells are capable of differentiating into
virtually any cell type in the human body. This imbues them
with great promise for scientific breakthroughs and medical
advances, but also raises serious ethical, legal and safety
concerns about their use.
Less controversial are “multipotent”
adult stem cells (ASCs) which do
not involve embryos or raise as
many safety concerns as
pluripotent cells.  ASCs are found
throughout the body.  Their ability
to differentiate is more limited than
pluripotent cells but is vast
nonetheless. The
NIH’s clinicaltrials.gov site lists some 4500 ASC trials as
compared with 27 for embryonic stem cells and 21 for induced
pluripotent stem cells. Recent announcements of new stem cell
treatments usually involve ASCs, such as last month’s news
that a toddler born without a trachea received a new one made
from her own adult stem cells.  It is therefore no surprise that
ASCs have captured the attention of researchers, investors,
physicians, patients and – increasingly – regulators, both here
and abroad.
A growing number of physicians routinely offer treatments
involving ASCs to their patients which can be performed in their
offices.  Autologous adult stem cells, used to treat a variety of
conditions, are harvested from the patient, processed, and
returned to the same patient. It is no surprise that moving ASCs
from laboratories to physician offices raises complex questions
of law. We consider one of the more pressing ones: to what
extent can the FDA regulate a physician’s ability to treat a
patient with that patient’s own stem cells?  In the coming
months, the D.C. Circuit Court of Appeals will hear oral
arguments on this very issue in United States v. Regenerative
Sciences.[2]
The Regenerative Sciences case originated in Colorado where
Christopher J. Centeno, M.D. and John R. Schultz, M.D. 
practicing jointly through the Centeno-Schultz Clinic (the Clinic),
developed and used the “Regenxx Procedure” (the
Procedure) to treat joint, muscle, bone and related conditions.
Drs. Centeno and Schultz are majority shareholders in
Regenerative Sciences (Regenerative) which owns the
Procedure, licenses it exclusively to the Clinic, and provided
laboratory services as part of the Clinic’s use of the Procedure
to treat patients. The Procedure involved taking blood and
bone marrow samples from the patient at the Clinic;
transporting them several miles to Regenerative where ASCs
were isolated and cultured to “expand” or produce more cells;
transporting them to the Colorado Genetics Laboratory for
visual inspection to confirm the absence of genetic
abnormalities; returning them to Regenerative; and some 4 to 6
weeks after initial extraction, transporting the resulting cell
product to the Clinic for reinjection at the patient’s site of injury
or degeneration. Patients reported significant improvement
while avoiding the physical and financial costs of invasive
surgery. In 2008 the FDA notified the two physicians,
Regenerative and Regenerative’s lab director that the
Regenxx Procedure cell product constituted a “drug” under
the Food Drug and Cosmetics Act[3] and a “biologic” under the
Public Health Service Act.[4] Consequently, the Procedure
could not be used without first obtaining pre-marketing
approval.
The FDA regulates medical drugs and devices under the FDCA
and biologics under the PHSA, and requires some form of pre-
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marketing approval for many of them. In doing so, however, it
typically deals with commercial pharmaceutical companies;
state law governs physicians in the practice of medicine. Thus,
while FDA regulations obviously affect the drugs, devices and
biologics available for physician use, they normally do not
target a physician’s actual treatment of a patient. Because
medical advances routinely occur “at the bedside” without FDA
oversight, the Regenerative defendants and the medical
profession at large were deservedly surprised to learn that the
FDA had decided to regulate autologous ASCs as human cell,
tissue and tissue-based products (HCT/Ps).[5]
The FDA’s HCT/P regulations can be found at 21 C.F.R. §
1271 and create a tiered framework based on PHSA §§ 351
and 361. We will not delve into its complexity here beyond
saying that the agency predicates the extent of regulation on
the degree of risk to a patient. PHSA § 361 provides minimal
oversight of low-risk HCT/Ps that are, inter alia, 1) no more
than minimally manipulated; 2)  used for their same original or
“homologous” purpose; and 3) autologous, i.e., the patient is
treated with her own cells. PHSA § 361 manufacturers must
comply with various registration and reporting requirements but
do not need to obtain pre-marketing approval before using the
HCT/P. In the FDA’s view, even though the Regenexx
Procedure is used for autologous (same patient) purposes, it
involved more than minimal manipulation. This made the
resulting cell product a “biologic” under PHSA §351 and a
“drug” under the FDCA.
Consequently, Regenerative had unwittingly become an
“establishment” that “manufactured” § 351 HCT/Ps. Treating a
patient with her own cells had become “marketing” in need of
prior approval by the FDA. Without pre-market approval, the
cell product – based on the patient’s own cells – had become
an “adulterated” and “misbranded” drug and biologic under the
FDCA and the PHSA. In effect, Regenerative would need to
submit to the same pre-marketing approval process as Pfizer,
the world’s leading pharmaceutical company with self-reported
revenues of $59 billion for 2012. This was true even though
Regenerative Sciences existed solely to enable its two
TM
physician-owners to extract, expand and re-inject a patient’s
cells for the sole purpose of restoring that patient’s function and
reducing that patient’s pain. Despite their dramatically different
resources, Regenerative and Pfizer would be equally required
to conform to Current Good Manufacturing Practices (CGMPs)
and conduct formal clinical trials – quite the challenge when
dealing with a patient who wants to use her own stem cells
now as opposed to several if not many years in the future.
Litigation ensued and the case was eventually tried in the
federal district court for the district of D.C. Regenerative
challenged the FDA’s authority to regulate at all, arguing: 1)
Congress never intended its Commerce Clause power to
interfere with the practice of medicine; and 2) there was no
interstate commerce since all activities were confined to
Colorado. The court disagreed, reasoning that state practice of
medicine laws do not preclude federal law from affecting and
effectively regulating certain aspects of a physician’s practice. 
Further, interstate commerce existed because the Procedure
used drugs shipped from out-of-state.
The court also upheld the FDA’s ability to regulate a patient’s
own cells. Although “a close call,” the court explained that the
Regenexx cell product falls within the FDCA’s technical
definition of a “drug” because it is an “article … intended to
affect the structure or function of the body ….” [6] It
simultaneously qualifies as a PHSA “biologic product” because
like a “therapeutic serum, … blood, blood component or
derivative, protein … or analogous  product,” it is “applicable to
prevention, treatment or cure of a disease or condition in
human beings.”[7]  Defendants’ website and pleadings showed
that the Regenexx Procedure and ASC treatment were
“intended to affect the structure or function of the body” and
“applicable to prevention, treatment or cure of a disease or
condition in human beings.”  The FDA therefore had authority
under both statutes to promulgate and enforce HCT/P
regulations, and tie the degree of oversight to the degree of cell
manipulation.  The Procedure’s “many steps” [8] could
constitute more than manipulation under § 351 and, in any
event, the agency’s finding of more than minimal manipulation
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deserved “substantial deference” by the court. Accordingly, the
court entered summary judgment for the FDA, dismissed all
counterclaims, and permanently enjoined use of the
Regenexx  Procedure. On appeal, each side has essentially
stood firm in their positions, with Regenerative receiving the
support of amici American Association of Orthopaedic
Medicine, the Association of American Physicians & Surgeons,
Inc. and Tim Turner (whose Parkinson’s disease has not
responded to available treatments).
At first glance, the idea of the FDA regulating our own cells
looks like an outrageous invasion of individual privacy and
denial of personal autonomy. If patients weigh risks and
benefits of medical treatments every day, why prevent them
from doing so with their own cells? This question is especially
compelling where a patient has few or no effective therapies,
and limited or no access to experimental treatments. That a
treatment may be more risky in the hands of untrained or
unskilled doctors is not unique to autologous adult stem cell
therapies; this problem pervades medical practice.
Despite the intuitive appeal of defendants’ position, a closer
look at the medical procedures, the applicable statutes and the
trial court’s assessment of both indicates that the FDA has the
stronger argument on all counts. Using components shipped
between states has frequently sufficed as interstate commerce
in past case law. The cell product and its intended use do fall
within the statute’s literal and technical definitions of a drug and
a biologic as well as the regulatory definition of a human cell,
tissue or tissue-based product.
If the agency’s power and discretion to regulate are upheld, the
facts of this case are problematic because the degree of
manipulation determines whether an HCT/P must satisfy the
burdensome criteria of § 351 or § 361’s comparatively milder
requirements. The Regenexx  Procedure involves “many
steps” to isolate and expand the cells including “selective
culture and expansion of a multitude of different types of blood-
forming and rare bone marrow stromal cells using plastic
flasks, additives and nutrients, and environmental conditions
TM
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such as temperature and humidity, to determine the growth and
biological characteristics of the resulting cell population.”[9] 
Over the course of 4 to 6 weeks, the cell product is moved
between several locations: the Clinic, the Regenerative
Sciences lab, an outside testing lab, back to Regenerative, and
back to the Clinic.
These facts create a strong case for finding minimal
manipulation. Plus, courts routinely defer to agency rule-
making, interpretation and enforcement especially in matters of
science and technology.  Although the arguments for each side
are more complex and nuanced, the big picture seems to show
that the stars are in alignment for the FDA which, in our
assessment, will likely prevail at the appellate level. This is not
to say that we hope the government succeeds in derailing
autologous adult stem cell therapies. We simply think the
rules of statutory interpretation and administrative procedure
will weigh in the agency’s favor in this case, especially with this
particular set of facts.
Regardless of how the D.C. Circuit resolves this case, one thing
is clear: the FDA should re-examine its HCT/P regulations
especially as applied to physicians treating patients with their
own cells. Extracting a patient’s cells for subsequent reinjection
undoubtedly carries risk – but so does banking one’s own blood
or freezing eggs for later use. Conditioning the extent of
regulation on the degree of manipulation may make sense on
paper but is vague and confusing in practice, especially in the
dynamic field of cellular therapies. In an age of relentless cost
inflation and limited therapies for debilitating illness, it makes no
sense to deprive patients of autologous therapies because their
physician lacks the resources – and patients lack the time – to
satisfy the pre-marketing requirements that oppress even
Merck and Johnson & Johnson. The FDA is obligated to protect
the public health as well as individual patients. Critical to this
mission is striking the proper balance of risks and benefits,
where the benefits include facilitating medical innovation. In the
context of adult stem cell regulation, especially autologous
cells, it is time for that risk-benefit balance to be recalibrated.
Stem cell therapies, even autologous ones, should be
regulated, but those regulations must be re-designed to fit
the parties and products being regulated. To be blunt, it
makes no sense for the FDA to insist that a practicing
physician who is treating an individual patient  must conform to
the same pre-marketing and manufacturing requirements that
bind large-scale, commercial pharmaceutical manufacturers
that produce drugs in bulk for mass distribution. Moreover, the
agency should not monopolize risk-benefit calculations to the
exclusion of patients who, with the counsel of their physicians,
want to make their own calls about using their own cells to treat
their own conditions. Preventing them from doing so is already
leading many patients to assume other and perhaps greater
forms of risk, such as seeking treatments in foreign clinics that
may or may not be up to the task.
Suing an agency is usually an uphill and often losing battle. We
doubt that Regenerative Sciences and cases of its kind will do
much to lower regulatory hurdles. Some form of regulation is
needed, but the FDA must recognize that its current HCT/P
framework is ill-suited to many kinds of cellular therapies.
It could revamp its HCT/P framework entirely, but that will take
time. In the near term, the agency should reach beyond
existing expert advisory committees and public comment
sessions. It should engage in a true collaboration with a wider
group of physicians and surgeons who are already using or
stand ready to use various types of autologous adult stem cell
therapies, and the patients who have had or want treatment.  It
can also look to the guidelines of relevant organizations, such
as the American Association of Blood Banks or various
physician organizations. Only then can the FDA get a firm
handle on what kinds of techniques and treatments present
tolerable levels of risk when balanced with the need for
innovation and the basic right of patients to use their own cells.
After all, patients are the ones who must bear the burdens of
illness, not the regulators, judges or attorneys.
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James Vanden Bosch on June 5, 2013 at 11:52 AM said:
Beautiful and insightful commentary! I, myself with
medical doctors throughout the world, have been in the
practice of autologous stem cell treatments for
orthopedic, Dr. Joseph Purita, neurological and
autoimmune conditions. I have seen many patients that
have the financial burdens of too costly of medical
treatments only to run out of options as conventional
treatment are not working. I have performed in excess
of over 6,000 treatments in the past 6 years to see
patients overcome illness where conventional therapies
have failed. Thank you.
Geoffrey Lomax on June 6, 2013 at 1:27 PM said:
A very comprehensive and informative review of the
state of regulation of autologous cell therapies and
some provocative thinking about the balance between
safety and freedom of choice. I expect we will be
struggling with this balance for the foreseeable future.
Thank you!
Technical note, the authors state:
The NIH’s clinicaltrials.gov site lists some 4500 ASC
trials as compared with 27 for embryonic stem cells and
21 for induced pluripotent stem cells.
I attempted to replicate the embryonic stem cells search
using different approaches (e.g. search term,
intervention and embryonic stem cells) with 26 resulting
records. An examination of the resulting records
reveals:
6 involve actual clinical interventions with hESC-based
therapies for eye disease
The remaining records are not “trails” involving hESC-
based interventions.
8 involve cell line differentiation, cell characterization or
biomarker studies
8 involve interventions using drugs, cord blood or other
adult cells
4 involve the derivation of cell lines
My current understanding is there are 6 hESC-based
clinical trials in progress and 1 trial has been
terminated. I mention this because the figure of 27 trials
is misleading, and it has already been disseminated on
social media.
Given the apparent 4-fold discrepancy between these
figures, I would encourage additional explanation of the
results or a revision of the reported number to best
reflect the state of the field.
Respectfully.
Geoffrey Lomax
CIRM
Paul Knoepfler on June 6, 2013 at 5:32 PM said:
The historical and legal perspectives in the first half of
the article are spot on and helpful.
However, parts of the later portion where you argue for
weakening of the regulation of propagated adult stem
cell therapies greatly concern me and you have left out
some very important elements that are key to
understanding the ongoing debate over the appropriate
level of regulatory oversight for stem cell therapies. For
example, you pretty much gloss over the safety
concerns related to these stem cell interventions.
It seems to me that changes are definitely needed at
the FDA in some respects related to stem cells such as
expanded compassionate use of stem cells for patients
with fatal diseases and a push for more openness. So
we agree on a need for change at the FDA on stem
cells. But the weakening of regulatory standards for
propagated adult stem cell interventions would greatly
increase patient risk. Further, as the numerous
outstanding adult stem cell biotechs such as Athersys
and Mesoblast have shown, in the stem cell field a
company can have its innovation and be compliant too.
Your statement, “Conditioning the extent of regulation
on the degree of manipulation may make sense on
paper but is vague and confusing in practice, especially
in the dynamic field of cellular therapies” is very
puzzling.
In fact, the degree of manipulation is operationally (not
just on paper) extremely important from a patient safety
perspective and it makes perfect common sense that
stem cells manipulated in different ways and to different
degrees should be subject to different regulations. I do
not see what’s vague or confusing about that at all.
On the other hand, your argument that smaller
companies producing stem cell drugs should not be
subject to the same regulations as larger companies is
a dangerous one. Since when is the law variable
depending on the size of the entity that should be
following that law? Just as small and large drug
manufacturers of pill (chemical) drugs have to follow the
same rules to provide data on safety and efficacy,
smaller companies selling stem cell drug interventions
should have to follow the same rules and laws as big
companies. To do otherwise would put patients at great
risk. Don’t underestimate the number of patients
collectively that stem cell clinics are treating and putting
at risk these days: the numbers are in the many
thousands and growing.
Paul Knoepfler
UC Davis
http://www.ipscell.com
Alexey on June 8, 2013 at 9:07 PM said:
As Goffrey pointed out, the authors completely off with
numbers of clinical trials. This is very misleading for the
public. Unlike the authors of this post, he spend some
time to read it through the trials (it’s easy thing to do for
iPS and hES trials) and got the right numbers.
Everyone can do this correct data mining. Just take
some time, before throw some numbers for public view.
As for iPS, out of 21 listed by authors in the post, 0
trials are therapeutic. Out of >4500 more than 70% are
drugs and combinations for hematopoietic progenitor
cell transplant for homologous use in hematology-
oncology. All of these assess drugs for conditioning
regimen or something else, but not efficacy of cells
themselves.
Finally, NCT database represents about 75% of world’s
available clinical trials registries and therefore doesn’t
give the whole picture.
Unfortunately, the authors are not addressing
comments above.
Alexey on June 9, 2013 at 2:19 AM said:
I think, everyone could agree, that FDA needs to reform
and tune up a current view (regulations) on some (or
many) kinds of cell therapy. I think, agency understands
it, but can’t modify the current law quickly, because of
novel and uncertain nature of cell therapies.
As Geoffrey pointed out, there is a huge discrepancy
between number of trials, indicated by authors and
reality. Unlike the authors, he did a great analysis and
came with a correct real picture. It is very important to
read through trials and understand what is all about.
Throwing numbers, retrieved by search results, without
sorting it out and hand coding, could mislead public
hugely.
As for iPS, out of 21 listed by authors in the post, 0
trials are therapeutic. Out of >4500 more than 70% are
drugs and combinations for hematopoietic progenitor
cell transplant for homologous use in hematology-
oncology. All of these assess drugs for conditioning
regimen or something else, but not efficacy of cells
themselves.
Finally, NCT database represents about 75% of world’s
available clinical trials registries and therefore doesn’t
give the whole picture
Gabriel Rosenfeld on June 11, 2013 at 3:22 PM said:
I really enjoyed this article having some experience on
the research side with embryonic stem cells. Perhaps
this is too simplistic but would it be unreasonable to
assert that patients suffering from degenerative or
terminal diseases be exempt from regulations on use of
their own cells from a humanitarian position? Well, not
exempt per se. I think it would be useful to mandate
reporting the specific therapy/patient progress to FDA to
Proudly powered by WordPress
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monitor effectiveness perhaps within a specified period
of time to allow the providers to patent their procedure.
Nonetheless, I think that Paul raises an important point
regarding safety if we simply allow small organizations
looser regulations.
